Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;15(8):725-30.
doi: 10.1007/s12603-011-0058-9.

Designing Phase II B trials in sarcopenia: the best target population

M Pahor  1 , M Cesari
Affiliations

Designing Phase II B trials in sarcopenia: the best target population

M Pahor et al. J Nutr Health Aging. 2011 Aug.

Abstract

Despite the existing limitations and controversies regarding the definition of sarcopenia and its clinical consequences, the current scientific evidence strongly suggests that muscle decline is a primary determinant of the disabling process (and likely of other major health-related events). In fact, the muscle loss (in terms of mass as well as strength) occurring with aging has been growingly associated with mobility impairment and disability in older persons. Unfortunately, current evidence is mainly from observational studies. Times are mature to begin testing interventions aimed at modifying the sarcopenia process through the design and development of specific clinical trials. Considering the emergence of many promising interventions towards this age-related condition (e.g., physical exercise [in particular, resistance training], testosterone, antioxidant supplementations), the need for Phase II trial designs is high. In the present report, we discuss which are the major issues related to the design of Phase II clinical trials on sarcopenia with particular focus on the participant's characteristics to be considered as possible inclusion and exclusion criteria.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Number of articles in PubMed on "sarcopenia" according to publication year.
See this image and copyright information in PMC

References

    1. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5 Suppl):990S. - PubMed
    1. Abellan van Kan G, Andre E, Bischoff Ferrari HA, Boirie Y, Onder G, Pahor M, et al. Carla Task Force on Sarcopenia: propositions for clinical trials. J Nutr Health Aging. 2009;13(8):700. - PMC - PubMed
    1. Cesari M, Ferrini A, Zamboni V, Pahor M. Sarcopenia: current clinical and research issues. Open Geriatr Med J. 2008;1(14)
    1. Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R. Skeletal muscle cutpoints associated with elevated physical disability risk in older men and women. Am J Epidemiol. 2004;159(4):413. - PubMed
    1. Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E, et al. Leg muscle mass and composition in relation to lower extremity performance in men and women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc. 2002;50(5):897. - PubMed

Publication types